Understanding variability in the pharmacokinetics of atypical antipsychotics – focus on clozapine, olanzapine and aripiprazole population models

References

• Aichhorn W, Marksteiner J, Walch T, Zernig G, Hinterhuber H, Stuppaeck C, Kemmler G. 2007. Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents. J Child Adolesc Psychopharmacol. 17(5):665–674.
   PubMed Web of Science ®Google Scholar
• Aichhorn W, Whitworth AB, Weiss EM, Marksteiner J. 2006. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Saf. 29(7):587–598.
   PubMed Web of Science ®Google Scholar
• Akamine Y, Sugawara-Kikuchi Y, Uno T, Shimizu T, Miura M. 2017. Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms. Ann Clin Biochem. 54(6):677–685.
   PubMed Web of Science ®Google Scholar
• Bachmann CJ, Haberhausen M, Heinzel-Gutenbrunner M, Remschmidt H, Theisen FM. 2008. Large intraindividual variability of olanzapine serum concentrations in adolescent patients. Ther Drug Monit. 30(1):108–112.
   PubMed Web of Science ®Google Scholar
• Bachmann CJ, Rieger-Gies A, Heinzel-Gutenbrunner M, Hiemke C, Remschmidt H, Theisen FM. 2008. Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia. Ther Drug Monit. 30(4):462–466.
   PubMed Web of Science ®Google Scholar
• Bauer RJ. 2011–2019. NONMEM Users Guides. Icon Development Solutions Ellicott City, Maryland, USA.
   Google Scholar
• Beal SL, Sheiner LB, Boeckmann AJ. 1989–2011. NONMEM Users Guides. Icon Development Solutions, Ellicott City, Maryland, USA.
   Google Scholar
• Bell R, McLaren A, Gaianos J, Copolov D. 1998. The clinical use of plasma clozapine levels. Aust N Z J Psychiatry. 32(4):567–574.
   PubMed Web of Science ®Google Scholar
• Belmonte C, Ochoa D, Roman M, Saiz-Rodriguez M, Wojnicz A, Gomez-Sanchez CI, Martin-Vilchez S, Abad-Santos F. 2018. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 polymorphisms on pharmacokinetics and safety of aripiprazole in healthy volunteers. Basic Clin Pharmacol Toxicol. 122(6):596–605.
   PubMed Web of Science ®Google Scholar
• Bergemann N, Frick A, Parzer P, Kopitz J. 2004. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry. 37(2):63–68.
   PubMed Web of Science ®Google Scholar
• Bigos KL, Bies RR, Pollock BG. 2006. Population pharmacokinetics in geriatric psychiatry. Am J Geriatr Psychiatry. 14(12):993–1003.
   PubMed Web of Science ®Google Scholar
• Bigos KL, Bies RR, Pollock BG, Lowy JJ, Zhang F, Weinberger DR. 2011. Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. Mol Psychiatry. 16(6):620–625.
   PubMed Web of Science ®Google Scholar
• Bigos KL, Pollock BG, Coley KC, Miller DD, Marder SR, Aravagiri M, Kirshner MA, Schneider LS, Bies RR. 2008. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 48(2):157–165.
   PubMed Web of Science ®Google Scholar
• Bowles TM, Levin GM. 2003. Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother. 37(5):687–694.
   PubMed Web of Science ®Google Scholar
• Brennan MD. 2014. Pharmacogenetics of second-generation antipsychotics. Pharmacogenomics. 15(6):869–884.
   PubMed Web of Science ®Google Scholar
• Caccia S. 2013. Safety and pharmacokinetics of atypical antipsychotics in children and adolescents. Pediatr Drugs. 15(3):217–233.
   PubMed Web of Science ®Google Scholar
• Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. 1999. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 37(3):177–193.
   PubMed Web of Science ®Google Scholar
• Castberg I, Spigset O. 2007. Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service. Pharmacopsychiatry. 40(3):107–110.
   PubMed Web of Science ®Google Scholar
• Castberg I, Westin AA, Skogvoll E, Spigset O. 2017. Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine. Acta Psychiatr Scand. 136(5):455–464.
   PubMed Web of Science ®Google Scholar
• Cheng Y. F, Lundberg T, Bondesson U, Lindstr M L, Gabrielsson J. 1988. Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur J Clin Pharmacol. 34(5):445–449.
   PubMed Web of Science ®Google Scholar
• Choc MG, Hsuan F, Honigfeld G, Robinson WT, Ereshefsky L, Crismon ML, Saklad SR, Hirschowitz J, Wagner R. 1990. Single- vs multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharm Res. 7(4):347–351.
   PubMed Web of Science ®Google Scholar
• Choc MG, Lehr RG, Hsuan F, Honigfeld G, Smith HT, Borison R, Volavka J. 1987. Multiple-dose pharmacokinetics of clozapine in patients. Pharm Res. 4(5):402–405.
   PubMed Web of Science ®Google Scholar
• Citrome L, Stauffer VL, Chen L, Kinon BJ, Kurtz DL, Jacobson JG, Bergstrom RF. 2009. Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. J Clin Psychopharmacol. 29(3):278–283.
   PubMed Web of Science ®Google Scholar
• Consoli G, Lastella M, Ciapparelli A, Catena Dell’Osso M, Ciofi L, Guidotti E, Danesi R, Dell’Osso L, Del Tacca M, Di Paolo A. 2009. ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. Pharmacogenomics. 10(8):1267–1276.
   PubMed Web of Science ®Google Scholar
• Cooper TB. 1996. Clozapine plasma level monitoring: current status. Psych Quart. 67(4):297–311.
   PubMed Web of Science ®Google Scholar
• Couchman L, Bowskill SV, Handley S, Patel MX, Flanagan RJ. 2013. Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged <18 years: data from a therapeutic drug monitoring service, 1994-2010. Early Interv Psychiatry. 7(2):122–130.
   PubMed Web of Science ®Google Scholar
• Couchman L, Morgan PE, Spencer EP, Flanagan RJ. 2010. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007. Ther Drug Monit. 32(4):438–447.
   PubMed Web of Science ®Google Scholar
• Dailly E, Urien S, Chanut E, Claudel B, Guerra N, Fernandez C, Jolliet P, Bourin M. 2002. Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter- and intraindividual variations of clozapine clearance. Prog Neuropsychopharmacol Biol Psychiatry. 26(4):699–703.
   PubMed Web of Science ®Google Scholar
• Darby JK, Pasta DJ, Wilson MG, Herbert J. 2008. Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study. Clin Drug Investig. 28(9):553–564.
   PubMed Web of Science ®Google Scholar
• Davies SJ, Mulsant BH, Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Kirshner MM, Sorisio D, Pollock BG, Bies RR. 2015. The impact of sertraline co-administration on the pharmacokinetics of olanzapine: a population pharmacokinetic analysis of the STOP-PD. Clin Pharmacokinet. 54(11):1161–1168.
   PubMed Web of Science ®Google Scholar
• DeLeon A, Patel NC, Crismon ML. 2004. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 26(5):649–666.
   PubMed Web of Science ®Google Scholar
• Dhillon S. 2012. Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder. Drugs. 72(1):133–162.
   PubMed Web of Science ®Google Scholar
• Diaz FJ, Santoro V, Spina E, Cogollo M, Rivera TE, Botts S, de Leon J. 2008. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry. 41(3):81–91.
   PubMed Web of Science ®Google Scholar
• Doude van Troostwijk LJ, Koopmans RP, Vermeulen HD, Guchelaar HJ. 2003. CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients. Eur J Pharm Sci. 20(4-5):451–457.
   PubMed Web of Science ®Google Scholar
• Eap CB, Bender S, Jaquenoud Sirot E, Cucchia G, Jonzier-Perey M, Baumann P, Allorge D, Broly F. 2004. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol. 24(2):214–219.
   PubMed Web of Science ®Google Scholar
• Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L. 2003. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol. 44(5):439–446.
   Web of Science ®Google Scholar
• Fabrazzo M, La Pia S, Monteleone P, Esposito G, Pinto A, De S L, Bencivenga R, Maj M. 2002. Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. Neuropsychopharmacology. 27(6):1050–1055.
   PubMed Web of Science ®Google Scholar
• FDA Aripiprazole. 2019. Food and Drug Administration prescribing information for ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension, for intramuscular use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207533s013lbl.pdf.
   Google Scholar
• Findling RL, Kauffman RE, Sallee FR, Carson WH, Nyilas M, Mallikaarjun S, Shoaf SE, Forbes RA, Boulton DW, Pikalov A. 2008. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study. J Clin Psychopharmacol. 28(4):441–446.
   PubMed Web of Science ®Google Scholar
• Findling RL, Kauffman R, Sallee FR, Salazar DE, Sahasrabudhe V, Kollia G, Kornhauser DM, Vachharajani NN, Assuncao-Talbott S, Mallikaarjun S, et al. 2009. An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder. J Child Adolesc Psychopharmacol. 19(4):431–439.
   PubMed Web of Science ®Google Scholar
• Fitton A, Heel RC. 1990. Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs. 40(5):722–747.
   PubMed Web of Science ®Google Scholar
• Frazier JA, Cohen LG, Jacobsen L, Grothe D, Flood J, Baldessarini RJ, Piscitelli S, Kim GS, Rapoport JL. 2003. Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. J Clin Psychopharmacol. 23(1):87–91.
   PubMed Web of Science ®Google Scholar
• Freeman DJ, Oyewumi LK. 1997. Will routine therapeutic drug monitoring have a place in clozapine therapy?. Clin Pharmacokinet. 32(2):93–100.
   PubMed Web of Science ®Google Scholar
• Golubovic B, Prostran M, Miljkovic B, Vucicevic K, Radivojevic D, Grabnar I. 2016. Population pharmacokinetic approach of immunosuppressive therapy in kidney transplant patients. CMC. 23(19):1998–2011.
   PubMed Web of Science ®Google Scholar
• Grothe DR, Calis KA, Jacobsen L, Kumra S, DeVane CL, Rapoport JL, Bergstrom RF, Kurtz DL. 2000. Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. J Clin Psychopharmacol. 20(2):220–225.
   PubMed Web of Science ®Google Scholar
• Grundmann M, Kacirova I, Urinovska R. 2014. Therapeutic drug monitoring of atypical antipsychotic drugs. Acta Pharm. 64(4):387–401.
   PubMed Web of Science ®Google Scholar
• Guitton C, Kinowski JM, Abbar M, Chabrand P, Bressolle F. 1999. Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia. J Clin Pharmacol. 39(7):721–728.
   PubMed Web of Science ®Google Scholar
• Hagg S, Spigset O, Mjorndal T, Dahlqvist R. 2000. Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 49(1):59–63.
   PubMed Web of Science ®Google Scholar
• Hard ML, Mills RJ, Sadler BM, Turncliff RZ, Citrome L. 2017a. Aripiprazole lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia. J Clin Psychopharmacol. 37(3):289–295.
   PubMed Web of Science ®Google Scholar
• Hard ML, Mills RJ, Sadler BM, Wehr AY, Weiden PJ, von Moltke L. 2017b. Pharmacokinetic profile of a 2-month dose regimen of aripiprazole lauroxil: a phase I study and a population pharmacokinetic model. CNS Drugs. 31(7):617–624.
   PubMed Web of Science ®Google Scholar
• Hard ML, Wehr AY, Sadler BM, Mills RJ, von Moltke L. 2018. Population pharmacokinetic analysis and model-based simulations of aripiprazole for a 1-day initiation regimen for the long-acting antipsychotic aripiprazole lauroxil. Eur J Drug Metab Pharmacokinet. 43(4):461–469.
   PubMed Web of Science ®Google Scholar
• Hefner G, Shams ME, Unterecker S, Falter T, Hiemke C. 2016. Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels. Psychopharmacology. 233(9):1695–1705.
   PubMed Web of Science ®Google Scholar
• Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C. 2018. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 51(1-02):e1.
   PubMed Web of Science ®Google Scholar
• Ismail Z, Wessels AM, Uchida H, Ng W, Mamo DC, Rajji TK, Pollock BG, Mulsant BH, Bies RR. 2012. Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. Am J Geriatr Psychiatry. 20(1):53–60.
   PubMed Web of Science ®Google Scholar
• Jann MW, Grimsley SR, Gray EC, Chang WH. 1993. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet. 24(2):161–176.
   PubMed Web of Science ®Google Scholar
• Jaquenoud Sirot E, Knezevic B, Morena GP, Harenberg S, Oneda B, Crettol S, Ansermot N, Baumann P, Eap CB. 2009. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol. 29(4):319–326.
   PubMed Web of Science ®Google Scholar
• Jeon JY, Chae SW, Kim MG. 2016. Population pharmacokinetics of aripiprazole in healthy Korean subjects. CP. 54(04):293–304.
   Web of Science ®Google Scholar
• Jerling M, Merle Y, Mentre F, Mallet A. 2003. Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. Br J Clin Pharmacol. 44(5):447–453.
   Web of Science ®Google Scholar
• Jukic MM, Smith RL, Haslemo T, Molden E, Ingelman-Sundberg M. 2019. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. Lancet Psychiatry. 6(5):418–426.
   PubMed Web of Science ®Google Scholar
• Kennedy WK, Jann MW, Kutscher EC. 2013. Clinically significant drug interactions with atypical antipsychotics. CNS Drugs. 27(12):1021–1048.
   PubMed Web of Science ®Google Scholar
• Kim JR, Seo HB, Cho JY, Kang DH, Kim YK, Bahk WM, Yu KS, Shin SG, Kwon JS, Jang IJ. 2008. Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. Br J Clin Pharmacol. 66(6):802–810.
   PubMed Web of Science ®Google Scholar
• Kirschbaum KM, Uhr M, Holthoewer D, Namendorf C, Pietrzik C, Hiemke C, Schmitt U. 2010. Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice. Neuropharmacology. 59(6):474–479.
   PubMed Web of Science ®Google Scholar
• Knights J, Rohatagi S. 2015. Development and application of an aggregate adherence metric derived from population pharmacokinetics to inform clinical trial enrichment. J Pharmacokinet Pharmacodyn. 42(3):263–273.
   PubMed Web of Science ®Google Scholar
• Koue T, Kubo M, Funaki T, Fukuda T, Azuma J, Takaai M, Kayano Y, Hashimoto Y. 2007. Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. Biol Pharm Bull. 30(11):2154–2158.
   PubMed Web of Science ®Google Scholar
• Krivoy A, Gaughran F, Weizman A, Breen G, MacCabe JH. 2016. Gene polymorphisms potentially related to the pharmacokinetics of clozapine: a systematic review. Int Clin Psychopharmacol. 31(4):179–184.
   PubMed Web of Science ®Google Scholar
• Lane HY, Chang YC, Chang WH, Lin SK, Tseng YT, Jann MW. 1999. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry. 60(1):36–40.
   PubMed Web of Science ®Google Scholar
• Lee J, Bies R, Takeuchi H, Fervaha G, Bhaloo A, Powell V, Remington G. 2016. Quantifying intraindividual variations in plasma clozapine levels: a population pharmacokinetic approach. J Clin Psychiatry. 77(05):681–687.
   PubMed Web of Science ®Google Scholar
• Lee ST, Ryu S, Kim SR, Kim MJ, Kim S, Kim JW, Lee SY, Hong KS. 2012. Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response. J Clin Psychopharmacol. 32(4):441–448.
   PubMed Web of Science ®Google Scholar
• Lexicomp Aripiprazole. 2019. Wolters Kluwer Clinical Drug Information. https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669675?searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Daripiprazole%26t%3Dname%26va%3Daripiprazole.
   Google Scholar
• Lexicomp Clozapine. 2019. Wolters Kluwer Clinical Drug Information. https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669830?searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dclozapine%26t%3Dname%26va%3Dclozapine.
   Google Scholar
• Lexicomp Olanzapine. 2019. Wolters Kluwer Clinical Drug Information. https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669793?searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dolanzapine%26t%3Dname%26va%3Dolanzapine.
   Google Scholar
• Li A, Ji S, Yue W, Yan H, Dong F, Ruan C, Li W, Lu W, Zhang D, Wang C. 2018. Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia. BMJ Open. 8(8):e020070.
   PubMed Web of Science ®Google Scholar
• Li LJ, Shang DW, Li WB, Guo W, Wang XP, Ren YP, Li AN, Fu PX, Ji SM, Lu W, et al. 2012. Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia. Acta Pharmacol Sin. 33(11):1409–1416.
   PubMed Web of Science ®Google Scholar
• Lobo ED, Robertson-Plouch C, Quinlan T, Hong Q, Bergstrom RF. 2010. Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model. Paediatr Drugs. 12(3):201–211.
   PubMedGoogle Scholar
• Lund BC, Perry PJ. 2000. Olanzapine: an atypical antipsychotic for schizophrenia. Expert Opin Pharmacother. 1(2):305–323.
   PubMedGoogle Scholar
• Mallikaarjun S, Kane JM, Bricmont P, McQuade R, Carson W, Sanchez R, Forbes RA, Fleischhacker WW. 2013. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res. 150(1):281–288.
   PubMed Web of Science ®Google Scholar
• Mallikaarjun S, Salazar DE, Bramer SL. 2004. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol. 44(2):179–187.
   PubMed Web of Science ®Google Scholar
• Mallikaarjun S, Shoaf SE, Boulton DW, Bramer SL. 2008. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole. Clin Pharmacokinet. 47(8):533–542.
   PubMed Web of Science ®Google Scholar
• Markowitz JS, DeVane CL, Malcolm RJ, Gefroh HA, Wang JS, Zhu HJ, Donovan JL. 2006. Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J Clin Pharmacol. 46(2):164–171.
   PubMed Web of Science ®Google Scholar
• Mauri MC, Paletta S, Di Pace C, Reggiori A, Cirnigliaro G, Valli I, Altamura AC. 2018. Clinical pharmacokinetics of atypical antipsychotics: an update. Clin Pharmacokinet. 57(12):1493–1528.
   PubMed Web of Science ®Google Scholar
• Mayerova M, Ustohal L, Jarkovsky J, Pivnicka J, Kasparek T, Ceskova E. 2018. Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations. NDT. 14:1535–1543.
   Web of Science ®Google Scholar
• McIntyre RS, Soczynska JK, Woldeyohannes HO, Miranda A, Konarski JZ. 2007. Aripiprazole: pharmacology and evidence in bipolar disorder. Expert Opin Pharmacother. 8(7):1001–1009.
   PubMed Web of Science ®Google Scholar
• Melkersson KI, Scordo MG, Gunes A, Dahl ML. 2007. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. J Clin Psychiatry. 68(05):697–704.
   PubMed Web of Science ®Google Scholar
• Miller DD, Fleming F, Holman TL, Perry PJ. 1994. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry. 55 Suppl B:117–121.
   PubMed Web of Science ®Google Scholar
• Mitchell M, Kothare P, Bergstrom R, Zhao F, Jen KY, Walker D, Johnson J, McDonnell D. 2013. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia. Clin Ther. 35(12):1890–1908.
   PubMed Web of Science ®Google Scholar
• Moons T, de Roo M, Claes S, Dom G. 2011. Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics. 12(8):1193–1211.
   PubMed Web of Science ®Google Scholar
• Mould DR, Upton RN. 2012. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol. 1:e6.
   PubMedGoogle Scholar
• Mould DR, Upton RN. 2013. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2:e38.
   PubMedGoogle Scholar
• Na Takuathung M, Hanprasertpong N, Teekachunhatean S, Koonrungsesomboon N. 2019. Impact of CYP1A2 genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and meta-analysis. Acta Psychiatr Scand. 139(1):15–25.
   PubMed Web of Science ®Google Scholar
• Ng W, Uchida H, Ismail Z, Mamo DC, Rajji TK, Remington G, Sproule B, Pollock BG, Mulsant BH, Bies RR. 2009. Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. Ther Drug Monit. 31(3):360–366.
   PubMed Web of Science ®Google Scholar
• Olmos I, Ibarra M, Vazquez M, Maldonado C, Fagiolino P, Giachetto G. 2019. Population pharmacokinetics of clozapine and norclozapine and switchability assessment between brands in Uruguayan patients with schizophrenia. Biomed Res Int. 2019:3163502.
   PubMed Web of Science ®Google Scholar
• Ozdemir V, Kalow W, Okey AB, Lam MS, Albers LJ, Reist C, Fourie J, Posner P, Collins EJ, Roy R. 2001. Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C–>A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J Clin Psychopharmacol. 21(6):603–607.
   PubMed Web of Science ®Google Scholar
• Palego L, Biondi L, Giannaccini G, Sarno N, Elmi S, Ciapparelli A, Cassano G B, Lucacchini A, Martini C, Dell'Osso L. 2002. Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables. Prog Neuropsychopharmacol Biol Psychiatry. 26(3):473–480.
   PubMed Web of Science ®Google Scholar
• Patteet L, Morrens M, Maudens KE, Niemegeers P, Sabbe B, Neels H. 2012. Therapeutic drug monitoring of common antipsychotics. Ther Drug Monit. 34(6):629–651.
   PubMed Web of Science ®Google Scholar
• Perera V, Bies RR, Mo G, Dolton MJ, Carr VJ, McLachlan AJ, Day RO, Polasek TM, Forrest A. 2014. Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice. Br J Clin Pharmacol. 78(4):800–814.
   PubMed Web of Science ®Google Scholar
• Perera V, Gross AS, Polasek TM, Qin Y, Rao G, Forrest A, Xu J, McLachlan AJ. 2013. Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia. Expert Opin Drug Metab Toxicol. 9(9):1115–1137.
   PubMed Web of Science ®Google Scholar
• Pilla Reddy V, Kozielska M, Suleiman AA, Johnson M, Vermeulen A, Liu J, de Greef R, Groothuis GM, Danhof M, Proost JH. 2013. Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: the use of PANSS total score and clinical utility. Schizophr Res. 146(1-3):144–152.
   PubMed Web of Science ®Google Scholar
• Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S, Jin Y, Richmond G, Carreon D, Sitanggan K, Gerber B. 1994. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry. 55 Suppl B:133–136.
   PubMed Web of Science ®Google Scholar
• Remington G, Agid O, Foussias G, Ferguson L, McDonald K, Powell V. 2013. Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology. 225(3):505–518.
   PubMed Web of Science ®Google Scholar
• Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ. 2004. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol. 24(1):70–78.
   PubMed Web of Science ®Google Scholar
• Saiz-Rodriguez M, Belmonte C, Román M, Ochoa D, Jiang-Zheng C, Koller D, Mejía G, Zubiaur P, Wojnicz A, Abad-Santos F. 2018. Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants. Basic Clin Pharmacol Toxicol. 123(4):474–485.
   PubMed Web of Science ®Google Scholar
• Schaber G, Stevens I, Gaertner HJ, Dietz K, Breyer-Pfaff U. 1998. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. Br J Clin Pharmacol. 46(5):453–459.
   PubMed Web of Science ®Google Scholar
• Schwenger E, Dumontet J, Ensom MH. 2011. Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia? Clin Pharmacokinet. 50(7):415–428.
   PubMed Web of Science ®Google Scholar
• Shang DW, Li LJ, Wang XP, Wen YG, Ren YP, Guo W, Li WB, Li L, Zhou TY, Lu W, et al. 2014. Population pharmacokinetic/pharmacodynamic model of clozapine for characterizing the relationship between accumulated exposure and PANSS scores in patients with schizophrenia. Ther Drug Monit. 36(3):378–386.
   PubMed Web of Science ®Google Scholar
• Sheehan JJ, Sliwa JK, Amatniek JC, Grinspan A, Canuso CM. 2010. Atypical antipsychotic metabolism and excretion. CDM. 11(6):516–525.
   Web of Science ®Google Scholar
• SmPC Aripiprazole. 2019. Summary of Product Characteristic for Aripiprazole 10 mg Tablets. https://www.medicines.org.uk/emc/product/7016/smpc.
   Google Scholar
• SmPC Clozapine. 2019. Summary of Product Characteristic for Clozaril 25 mg Tablets. https://www.medicines.org.uk/emc/product/4411/smpc.
   Google Scholar
• SmPC Olanzapine. 2019. Summary of Product Characteristic for Olanzapine 10mg Tablets. https://www.medicines.org.uk/emc/product/3070/smpc.
   Google Scholar
• Soderberg MM, Dahl ML. 2013. Pharmacogenetics of olanzapine metabolism. Pharmacogenomics. 14(11):1319–1336.
   PubMed Web of Science ®Google Scholar
• Spina E, de Leon J. 2015. Clinical applications of CYP genotyping in psychiatry. J Neural Transm. 122(1):5–28.
   PubMed Web of Science ®Google Scholar
• Stark A, Scott J. 2012. A review of the use of clozapine levels to guide treatment and determine cause of death. Aust N Z J Psychiatry. 46(9):816–825.
   PubMed Web of Science ®Google Scholar
• Swainston Harrison T, Perry CM. 2004. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 64(15):1715–1736.
   PubMed Web of Science ®Google Scholar
• Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ, et al. 2011. Pharmacogenetics: from bench to byte-an update of guidelines. Clin Pharmacol Ther. 89(5):662–673.
   PubMed Web of Science ®Google Scholar
• Tang YL, Mao P, Li FM, Li W, Chen Q, Jiang F, Cai ZJ, Mitchell PB. 2007. Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia. Br J Clin Pharmacol. 64(1):49–56.
   PubMed Web of Science ®Google Scholar
• Taylor D. 1997. Pharmacokinetic interactions involving clozapine. Br J Psychiatry. 171(2):109–112.
   PubMed Web of Science ®Google Scholar
• Telles-Correia D, Barbosa A, Cortez-Pinto H, Campos C, Rocha NB, Machado S. 2017. Psychotropic drugs and liver disease: a critical review of pharmacokinetics and liver toxicity. WJGPT. 8(1):26–38.
   Google Scholar
• Theisen FM, Haberhausen M, Schulz E, Fleischhaker C, Clement HW, Heinzel-Gutenbrunner M, Remschmidt H. 2006. Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication. Ther Drug Monit. 28(6):750–759.
   PubMed Web of Science ®Google Scholar
• Toth K, Csukly G, Sirok D, Belic A, Kiss A, Hafra E, Deri M, Menus A, Bitter I, Monostory K. 2017. Potential role of patients’ CYP3A-status in clozapine pharmacokinetics. Int J Neuropsychopharmacol. 20(7):529–537.
   PubMed Web of Science ®Google Scholar
• Tsuda Y, Saruwatari J, Yasui-Furukori N. 2014. Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. BMJ Open. 4(3):e004216
   PubMed Web of Science ®Google Scholar
• Urichuk L, Prior TI, Dursun S, Baker G. 2008. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. CDM. 9(5):410–418.
   Web of Science ®Google Scholar
• Wang JS, Taylor R, Ruan Y, Donovan JL, Markowitz JS, Lindsay De Vane C. 2004. Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacol. 29(3):551–557.
   PubMed Web of Science ®Google Scholar
• Wang JS, Zhu HJ, Donovan JL, Yuan HJ, Markowitz JS, Geesey ME, Devane CL. 2009. Aripiprazole brain concentration is altered in P-glycoprotein deficient mice. Schizophr Res. 110(1-3):90–94.
   PubMed Web of Science ®Google Scholar
• Whitney Z, Boyda HN, Procyshyn RM, Elbe D, Black T, Eslami A, Barr AM. 2015. Therapeutic drug levels of second generation antipsychotics in youth: a systematic review. J Child Adolesc Psychopharmacol. 25(3):234–245.
   PubMed Web of Science ®Google Scholar
• Yin A, Shang D, Wen Y, Li L, Zhou T, Lu W. 2016. Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis. Eur J Clin Pharmacol. 72(8):933–944.
   PubMed Web of Science ®Google Scholar
• Zhang X, Xiang Q, Zhao X, Ma L, Cui Y. 2019. Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: a systematic review and meta-analysis. J Clin Pharm Ther. 44(2):163–173.
   PubMed Web of Science ®Google Scholar